A recent study reveals that patients who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a leading medical journal demonstrates that while overweight people can lose about a fifth of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People buying these treatments need to be informed of the potential of quick weight regain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to original weight within about one and a half years.
Weighing Therapies
The research, which looked at dozens of trials involving over 9,000 of participants, compared the outcomes of these new drugs with older methods.
The team point out that individuals who shed pounds through dieting usually have a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Nutrition scientists believe the way of the drugs explains the accelerated regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal may cause the system to produce less of its own natural hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication leads to hunger is no longer kept in check, making binge eating a significant risk."
An Ongoing Condition?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts say that, due to the significant potential of relapse, the treatment should be considered long-term.
This view is echoed by pharmaceutical companies, who say that the results "underscore the chronic nature of obesity," similar to managing diseases like hypertension.
Patient Testimonies
Individuals who have come off the medication explain a sudden resurgence of appetite.
"I experienced a switch activating and I was suddenly starving," described a patient.
The struggle is worsened if patients have not adopted permanent lifestyle or habit changes during therapy.
Significant Adoption
Survey data show that millions of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is more common among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, experts caution that while the jabs are powerful agents for weight loss, they are not a magic fix and lasting health benefits relies on combined behavioural changes.
